Cargando…
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
Autores principales: | Barrière, J., Chamorey, E., Adjtoutah, Z., Castelnau, O., Mahamat, A., Marco, S., Petit, E., Leysalle, A., Raimondi, V., Carles, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080507/ https://www.ncbi.nlm.nih.gov/pubmed/33932508 http://dx.doi.org/10.1016/j.annonc.2021.04.019 |
Ejemplares similares
-
Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey
por: Barrière, J., et al.
Publicado: (2021) -
Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
por: Re, Daniel, et al.
Publicado: (2022) -
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer
por: Funakoshi, Yohei, et al.
Publicado: (2022) -
Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021) -
Développement et validation d’un nomogramme pour prédire l’acceptation de la vaccination contre le SARS-CoV2 chez les patients atteints de cancer
por: Gal, J., et al.
Publicado: (2021)